High dose tirofiban versus standard therapy in primary PCI for ST-segment elevation myocardial infarction (STEMI)
Keywords:
High-dose Tirofiban, Standard therapy, Percutaneous coronary intervention, STEMI, Myocardial infarction, Antithrombotic therapy, Interventional cardiology, Cardiac catheterizationAbstract
Background: The goal of this randomized controlled study was to evaluate the safety and efficacy of high-dose tirofiban compared to standard care in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). Methods: This study was carried out at the Tertiary care hospital Rawalpindi (Pakistan) from June 2021 to December 2022. The administration of high-dose tirofiban or usual treatment was randomly assigned to a total of 600 individuals. The main outcome was the 30-day composite of major adverse cardiovascular events (MACE), that involved stroke, target vessel revascularization, repeat myocardial infarction, and all-cause mortality. Aside from problems related to bleeding, stent thrombosis was one of the secondary outcomes. Results: When compared to the group receiving conventional medication, the rate of the main endpoint was significantly reduced in the tirofiban group (5.7% vs. 10.3%, p=0.03). This was principally caused by a decline in target vessel revascularization and recurring myocardial infarction in the tirofiban category. In terms of stent thrombosis or hemorrhage problems, there wasn't no discernible difference among both groups. Conclusion: In patients receiving primary PCI for STEMI, high-dose tirofiban added to conventional treatment lowers the risk of MACE at 30 days.
Downloads
References
Adam, Z., & de Belder, M. A. (2010). Primary percutaneous coronary intervention for ST-elevation myocardial infarction. In Oxford Text Book of Interventional Cardiology (pp. 254-277). Oxford University Press, Oxford, UK.
Berger, J. S., Roe, M. T., Gibson, C. M., Kilaru, R., Green, C. L., Melton, L., ... & Armstrong, P. W. (2009). Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. American Heart Journal, 158(6), 998-1004. https://www.sciencedirect.com/science/article/pii/S0002870309008023
De Luca, G., Suryapranata, H., Ottervanger, J. P., & Antman, E. M. (2004). Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation, 109(10), 1223–1225. https://doi.org/10.1161/01.CIR.0000121424.76486.20
Gandhi, S., Khan, S., Wasim, A. U., Hassan, S. S. U., Anwar, A., Umar, S., & Afnan, M. (2023). The short-term outcomes of tirofiban use in primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction (STEMI). International Journal of Health Sciences, 6(S8), 6867–6876. https://doi.org/10.53730/ijhs.v6nS8.14036
Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., & Harrington, R. A. (2008). Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 133(6), 708S-775S. http://www.jvsmedicscorner.com/ICU-Blood_Transfusions_files/Chest-2008-Anticoagulation%20in%20Acute%20ST-Segment%20Elevation%20Myocardial%20Infarction.pdf
Lagerqvist, B., Fröbert, O., Olivecrona, G. K., Gudnason, T., Maeng, M., Alström, P., Andersson, J., Calais, F., Carlsson, J., Collste, O., Götberg, M., Hårdhammar, P., Ioanes, D., Kallryd, A., Linder, R., Lundin, A., Odenstedt, J., Omerovic, E., Puskar, V., Tödt, T., … James, S. K. (2014). Outcomes 1 year after thrombus aspiration for myocardial infarction. The New England journal of medicine, 371(12), 1111–1120. https://doi.org/10.1056/NEJMoa1405707
Levine, G.N. (2014). Cardiology Secrets. Elsevier Inc. https://doi.org/10.1016/C2011-0-07065-5
McClellan, K. J., & Goa, K. L. (1998). Tirofiban: a review of its use in acute coronary syndromes. Drugs, 56(6), 1067-1080. https://link.springer.com/article/10.2165/00003495-199856060-00017
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J. M., Morice, M. C., Maillard, L., Pansiéri, M., Choussat, R., Pinton, P., & ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (2001). Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England journal of medicine, 344(25), 1895–1903. https://doi.org/10.1056/NEJM200106213442503
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., ... & Braunwald, E. (2005). Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. Jama, 294(10), 1224-1232. https://jamanetwork.com/journals/jama/articlepdf/201519/joc50103.pdf
Van Werkum, J. W., Gerritsen, W. B. M., Kelder, J. C., Hackeng, C. M., Ernst, S. M., Deneer, V. H. M., ... & Berg, J. T. (2007). Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Netherlands Heart Journal, 15, 375-381.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
